Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Retained Earnings: 2020-2025

Historic Retained Earnings for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to -$682.4 million.

  • Xeris Biopharma Holdings' Retained Earnings fell 2.35% to -$682.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$682.4 million, marking a year-over-year decrease of 2.35%. This contributed to the annual value of -$671.9 million for FY2024, which is 8.89% down from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Retained Earnings stood at -$682.4 million, which was up 0.09% from -$683.0 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Retained Earnings ranged from a high of -$409.3 million in Q3 2021 and a low of -$683.0 million during Q2 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$651.0 million (2024), whereas its average is -$641.4 million.
  • Data for Xeris Biopharma Holdings' Retained Earnings shows a maximum YoY slumped of 36.38% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Retained Earnings stood at -$460.1 million in 2021, then dropped by 20.57% to -$554.8 million in 2022, then fell by 11.22% to -$617.0 million in 2023, then decreased by 8.89% to -$671.9 million in 2024, then decreased by 2.35% to -$682.4 million in 2025.
  • Its Retained Earnings stands at -$682.4 million for Q3 2025, versus -$683.0 million for Q2 2025 and -$681.1 million for Q1 2025.